Moreover, preclinical studies demonstrate the therapeutic potential of targeting complex I, as evidenced by decreased tumor growth in NDUFB8-depleted AA BLCA tumors. This evidence concerns the gene NDUFB8 and bladder transitional cell carcinoma.